No Data
No Data
Express News | PCT Therapeutics Shares Are Trading Lower. The Company Announced Interim Results From the Phase 2 PIVOT-HD Study of PTC518 in Huntington's Disease Patients
PTC Therapeutics Says FDA Lifts Clinical Hold On Investigational Study In Patients With Rare Weak Nerve Cell Disorder
Thursday, PTC Therapeutics Inc (NASDAQ:PTCT) shared interim results from the Phase 2 PIVOT-HD study of PTC518 in Huntington's disease (HD) patients.HD is an inherited condition in which nerve cells in
Sector Update: Health Care Stocks Lean Lower Pre-Bell Thursday
Health care stocks were lower pre-bell Thursday as the Health Care Select Sector SPDR Fund (XLV) was down 0.3% and iShares Biotechnology ETF (IBB) was recently declining by 0.3%. Jazz Pharmaceuticals
PTC Therapeutics Reports Favorable Interim Results in Huntington's Disease Study; US FDA Lifts Clinical Hold
PTC Therapeutics (PTCT) said Thursday that the US Food and Drug Administration has lifted the partial clinical hold on its PTC518 program following favorable interim results from the phase 2 PIVOT-HD
Express News | Royalty Pharma: PTC Therapeutics Exercised Option to Sell Half of Retained Royalties on Roche's Evrysdi to Co's Unit for About $242 Mln Upfront
Express News | PTC Therapeutics Shared Interim Results From Phase 2 PIVOT-HD Study Of PTC518 In Huntington's Disease, Showing Dose-dependent Lowering Of Mutant Huntingtin Protein In Blood/Cerebrospinal Fluid And Favorable Trends On Several Relevant Clinical Assessments
The Real Wojak : Do you have like a top 3-5 that you like more than all the other ones? This list is way too long
72991267 : Glad I have some $Candel Therapeutics (CADL.US)$ after my disastrous SBFM.